27 year old male with history of HIV infection and substance abuse disorder arrived at the ER presenting aggressive behavior, errors of judgment and conduct, ego dystonic complex, auditor...
3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy is being investigated as a potential treatment option for patients with posttraumatic stress disorder (PTSD). Previous animal MDM...
This pooled post hoc analysis compared the effects of a combination of olanzapine and samidorphan (OLZ/SAM) versus olanzapine on body weight after 12 weeks of treatment in patients with s...
This analysis evaluated extrapyramidal symptoms (EPS) across 2 pooled, 6-week, placebo-controlled monotherapy studies; a 6-month open-label extension (OLE) monotherapy study; and a 6-week...
This randomized, double-blind, placebo-controlled trial investigated the efficacy and safety of lumateperone 42mg for the treatment of a major depressive episode in patients with major de...
This meta-analysis aimed to assess the treatment effect of maintenance transcranial magnetic stimulation for depression. The analysis included 14 studies and 705 participants. Maintenance...
TV-46000 is a long-acting subcutaneous antipsychotic (LASCA). The SHINE study evaluated the long-term safety, tolerability, and effect of TV-46000 once monthly (q1m) and once every two mo...
This subgroup analysis of SUSTAIN-3 (NCT02782104), a phase 3, open-label extension study of esketamine nasal spray (ESK), assessed the long-term efficacy of flexibly dosed ESK in combinat...
In a long-term study (up to 6.6 years) of intermittently-dosed esketamine with daily antidepressant, early improvement in depression was maintained and no new safety signal was identified...
This subgroup analysis of SUSTAIN-3 (NCT02782104), an open-label extension study of esketamine nasal spray (ESK), assessed the long-term safety of flexibly dosed ESK in combination with a...